Infective Endocarditis in Belgium: Prospective Data in Adults from the ESC EORP European Endocarditis Registry
Authors:
- Bram RoosensBRBram Roosens
- Bernard CosynsBCBernard Cosyns
- Patrizio LancellottiPLPatrizio Lancellotti
- Cécile LarocheCLCécile Laroche
- Christine Selton-SutyCSChristine Selton-Suty
- Agnès PasquetAgnès Pasquet
- Johan De SutterJSJohan De Sutter
- Philippe UngerPUPhilippe Unger
- Bernard PaelinckBPBernard Paelinck
- Paul VermeerschPVPaul Vermeersch
- Andreea MotocAMAndreea Motoc
- Xavier GallooXGXavier Galloo
Open Access
- 28 February 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (5) , 1371
Abstract
(1) Background: infective endocarditis (IE) is a significant health concern associated with important morbidity and mortality. Only limited, often monocentric, retrospective data on IE in Belgium are available. This prospective study sought to assess the clinical characteristics and outcomes of Belgian IE patients in the ESC EORP European endocarditis (EURO-ENDO) registry; (2) Methods: 132 IE patients were identified based on the ESC 2015 criteria and included in six tertiary hospitals in Belgium; (3) Results: The average Belgian IE patient was male and 62.8 ± 14.9 years old. The native valve was most affected (56.8%), but prosthetic/repaired valves (34.1%) and intracardiac device-related (5.3%) IE are increasing. The most frequently identified microorganisms were S. aureus (37.2%), enterococci (15.5%), and S. viridans (15.5%). The most frequent complications were acute renal failure (36.2%) and embolic events (23.6%). Cardiac surgery was effectively performed when indicated in 71.7% of the cases. In-hospital mortality occurred in 15.7% of patients. Predictors of mortality in the multivariate analysis were S. aureus (HR = 2.99 [1.07–8.33], p = 0.036) and unperformed cardiac surgery when indicated (HR = 19.54 [1.91–200.17], p = 0.012). (4) Conclusion: This prospective EURO-ENDO ancillary analysis provides valuable contemporary insights into the profile, treatment, and clinical outcomes of IE patients in Belgium.Keywords
Funding Information
- Abbott Vascular Int. (2011–2021, 2009–2018, 2014–2021, 2009–2018, 2009–2019, 2009–2012, 2011–2019, 2011–2020, 2014–2017, 2016–2019, 2014–2016, 2009–2012, 2011–2014, 2014–2020, 2014–2016, 2009–2011, 2009–2021, 2019–2022)
- Amgen Cardiovascular (2011–2021, 2009–2018, 2014–2021, 2009–2018, 2009–2019, 2009–2012, 2011–2019, 2011–2020, 2014–2017, 2016–2019, 2014–2016, 2009–2012, 2011–2014, 2014–2020, 2014–2016, 2009–2011, 2009–2021, 2019–2022)
- AstraZeneca (2011–2021, 2009–2018, 2014–2021, 2009–2018, 2009–2019, 2009–2012, 2011–2019, 2011–2020, 2014–2017, 2016–2019, 2014–2016, 2009–2012, 2011–2014, 2014–2020, 2014–2016, 2009–2011, 2009–2021, 2019–2022)
- Bayer AG (2011–2021, 2009–2018, 2014–2021, 2009–2018, 2009–2019, 2009–2012, 2011–2019, 2011–2020, 2014–2017, 2016–2019, 2014–2016, 2009–2012, 2011–2014, 2014–2020, 2014–2016, 2009–2011, 2009–2021, 2019–2022)
- Boehringer Ingelheim (2011–2021, 2009–2018, 2014–2021, 2009–2018, 2009–2019, 2009–2012, 2011–2019, 2011–2020, 2014–2017, 2016–2019, 2014–2016, 2009–2012, 2011–2014, 2014–2020, 2014–2016, 2009–2011, 2009–2021, 2019–2022)
- Boston Scientific (2011–2021, 2009–2018, 2014–2021, 2009–2018, 2009–2019, 2009–2012, 2011–2019, 2011–2020, 2014–2017, 2016–2019, 2014–2016, 2009–2012, 2011–2014, 2014–2020, 2014–2016, 2009–2011, 2009–2021, 2019–2022)
- The Bristol Myers Squibb and Pfizer Alliance (2011–2021, 2009–2018, 2014–2021, 2009–2018, 2009–2019, 2009–2012, 2011–2019, 2011–2020, 2014–2017, 2016–2019, 2014–2016, 2009–2012, 2011–2014, 2014–2020, 2014–2016, 2009–2011, 2009–2021, 2019–2022)
- Daiichi Sankyo Europe GmbH (2011–2021, 2009–2018, 2014–2021, 2009–2018, 2009–2019, 2009–2012, 2011–2019, 2011–2020, 2014–2017, 2016–2019, 2014–2016, 2009–2012, 2011–2014, 2014–2020, 2014–2016, 2009–2011, 2009–2021, 2019–2022)
- The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2011–2021, 2009–2018, 2014–2021, 2009–2018, 2009–2019, 2009–2012, 2011–2019, 2011–2020, 2014–2017, 2016–2019, 2014–2016, 2009–2012, 2011–2014, 2014–2020, 2014–2016, 2009–2011, 2009–2021, 2019–2022)
- Edwards (2011–2021, 2009–2018, 2014–2021, 2009–2018, 2009–2019, 2009–2012, 2011–2019, 2011–2020, 2014–2017, 2016–2019, 2014–2016, 2009–2012, 2011–2014, 2014–2020, 2014–2016, 2009–2011, 2009–2021, 2019–2022)
- Gedeon Richter Plc. (2011–2021, 2009–2018, 2014–2021, 2009–2018, 2009–2019, 2009–2012, 2011–2019, 2011–2020, 2014–2017, 2016–2019, 2014–2016, 2009–2012, 2011–2014, 2014–2020, 2014–2016, 2009–2011, 2009–2021, 2019–2022)
- Menarini, Int. Op. (2011–2021, 2009–2018, 2014–2021, 2009–2018, 2009–2019, 2009–2012, 2011–2019, 2011–2020, 2014–2017, 2016–2019, 2014–2016, 2009–2012, 2011–2014, 2014–2020, 2014–2016, 2009–2011, 2009–2021, 2019–2022)
- MSD-Merck & Co. (2011–2021, 2009–2018, 2014–2021, 2009–2018, 2009–2019, 2009–2012, 2011–2019, 2011–2020, 2014–2017, 2016–2019, 2014–2016, 2009–2012, 2011–2014, 2014–2020, 2014–2016, 2009–2011, 2009–2021, 2019–2022)
- Novartis Pharma AG (2011–2021, 2009–2018, 2014–2021, 2009–2018, 2009–2019, 2009–2012, 2011–2019, 2011–2020, 2014–2017, 2016–2019, 2014–2016, 2009–2012, 2011–2014, 2014–2020, 2014–2016, 2009–2011, 2009–2021, 2019–2022)
- ResMed (2011–2021, 2009–2018, 2014–2021, 2009–2018, 2009–2019, 2009–2012, 2011–2019, 2011–2020, 2014–2017, 2016–2019, 2014–2016, 2009–2012, 2011–2014, 2014–2020, 2014–2016, 2009–2011, 2009–2021, 2019–2022)
- Sanofi (2011–2021, 2009–2018, 2014–2021, 2009–2018, 2009–2019, 2009–2012, 2011–2019, 2011–2020, 2014–2017, 2016–2019, 2014–2016, 2009–2012, 2011–2014, 2014–2020, 2014–2016, 2009–2011, 2009–2021, 2019–2022)
- Servier (2011–2021, 2009–2018, 2014–2021, 2009–2018, 2009–2019, 2009–2012, 2011–2019, 2011–2020, 2014–2017, 2016–2019, 2014–2016, 2009–2012, 2011–2014, 2014–2020, 2014–2016, 2009–2011, 2009–2021, 2019–2022)
- Vifor (2011–2021, 2009–2018, 2014–2021, 2009–2018, 2009–2019, 2009–2012, 2011–2019, 2011–2020, 2014–2017, 2016–2019, 2014–2016, 2009–2012, 2011–2014, 2014–2020, 2014–2016, 2009–2011, 2009–2021, 2019–2022)
This publication has 27 references indexed in Scilit:
- Epidemiologic and clinical characteristics of infective endocarditis: a single-center retrospective study in the Bronx, New YorkInfection, 2022
- Changing spectrum of infective endocarditis in India: An 11-year experience from an academic hospital in North IndiaIndian Heart Journal, 2021
- Long-term follow-up of patients with infective endocarditis in a tertiary referral centerInternational Journal of Cardiology, 2021
- Infective endocarditis in the Netherlands: current epidemiological profile and mortalityNetherlands Heart Journal, 2020
- Aortic valve repair in endocarditis: scope and resultsIndian Journal of Thoracic and Cardiovascular Surgery, 2019
- Real-world outcomes of surgery for native mitral valve endocarditisThe Journal of Thoracic and Cardiovascular Surgery, 2017
- Clinical Presentation, Etiology, and Outcome of Infective Endocarditis in the 21st CenturyArchives of internal medicine (1960), 2009
- A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart DiseaseEuropean Heart Journal, 2003
- Changing Profile of Infective EndocarditisResults of a 1-Year Survey in FranceJAMA, 2002
- Validation of a combined comorbidity indexJournal of Clinical Epidemiology, 1994